Successful Treatment of KIT D816V-positive, Imatinib-resistant Systemic Mastocytosis with Interferon-alpha

被引：12

作者：

Yoshida, Chikamasa ^{[1
]}

Takeuchi, Makoto ^{[1
]}

Tsuchiyama, Junjiro ^{[2
]}

Sadahira, Yoshito ^{[2
]}

机构：

[1] Natl Hosp Org Minami Okayama Med Ctr, Dept Internal Med, Div Hematol, Okayama, Japan

[2] Kawasaki Med Sch, Dept Pathol, Kurashiki, Okayama, Japan

来源：

INTERNAL MEDICINE | 2009年 / 48卷 / 22期

关键词：

mastocytosis; myeloproliferative neoplasm; KIT; imatinib; interferon-alpha; CLINICAL PHARMACOKINETICS; MAST-CELLS; DISORDERS; LEUKEMIA; OPTIONS;

D O I：

10.2169/internalmedicine.48.2294

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

We describe a case of systemic mastocytosis associated with myelodysplastic syndrome. The bone marrow showed multifocal clusters of mast cells and myeloid dysplasia. Sequencing of the KIT DNA revealed a point mutation at codon 816 including a substitution of valine for aspartic acid (D816V). The patient's tumor did not respond to imatinib; however, interferon-alpha reduced the bone marrow mast cells and serum total tryptase. The patient remains alive at one year after the diagnosis without disease progression.

引用

页码：1973 / 1978

页数：6

共 20 条

[1] Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit
Akin, C
Brockow, K
D'Ambrosio, C
Kirshenbaum, AS
Ma, YS
Longley, BJ
Metcalfe, DD
[J]. EXPERIMENTAL HEMATOLOGY, 2003, 31 (08) : 686 - 692
[2] Practical management of patients with chronic myeloid leukemia receiving imatinib
Deininger, MWN
O'Brien, SG
Ford, JM
Druker, BJ
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) : 1637 - 1647
[3] Clinical pharmacokinetics of quetiapine - An atypical antipsychotic
DeVane, CL
Nemeroff, CB
[J]. CLINICAL PHARMACOKINETICS, 2001, 40 (07) : 509 - 522
[4] Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor
Heinrich, MC
Griffith, DJ
Druker, BJ
Wait, CL
Ott, KA
Zigler, AJ
[J]. BLOOD, 2000, 96 (03) : 925 - 932
[5] Horny H-P., 2008, WHO classification of Tumours of Haematopoietic and Lymphoid Tissues, V4th, P54
[6] Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge
Horny, HP
Sotlar, K
Sperr, WR
Valent, P
[J]. JOURNAL OF CLINICAL PATHOLOGY, 2004, 57 (06) : 604 - 608
[7] Mast cells and mastocytosis
Metcalfe, Dean D.
[J]. BLOOD, 2008, 112 (04) : 946 - 956
[8] FIP1L1-PDGFRA fusion:: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia
Pardanani, A
Brockman, SR
Paternoster, SF
Flynn, HC
Ketterling, RP
Lasho, TL
Ho, CL
Li, CY
Dewald, GW
Tefferi, A
[J]. BLOOD, 2004, 104 (10) : 3038 - 3045
[9] Eosinophils are derived from the neoplastic clone in patients with systemic mastocytosis and eosinophilia
Pardanani, A
Reeder, T
Li, CY
Tefferi, A
[J]. LEUKEMIA RESEARCH, 2003, 27 (10) : 883 - 885
[10] Clinical pharmacokinetics of imatinib
Peng, B
Lloyd, P
Schran, H
[J]. CLINICAL PHARMACOKINETICS, 2005, 44 (09) : 879 - 894

← 1 2 →